… Interim positron emission tomography (PET) using the tracer, [ 18 F]fluorodeoxyglucose, …
with aggressive non-Hodgkin lymphomas. We assessed whether PET can guide therapy in …

… The PETAL trial is open for patients with newly diagnosed aggressive B cell or T cell non-Hodgkin
lymphomas … Therapy for patients with a negative pre-treatment PET scan is at the …

… of Aggressive Non-Hodgkin Lymphomas (PETAL) trial investigated the ability of [ 18 F]-… to
guide treatment in aggressive non-Hodgkin lymphomas. Patients with B cell lymphomas and a …

… benefit from targeted therapies (eg, activated B-cell-like [ABC] lymphomas). In the PETAL
trial, … or six blocks of an intensive Burkitt’s lymphoma protocol 2. Patients with a negative scan …

… Introduction: The PETAL trial … treatment changes, however, had no impact on outcome (ASH
2014, abstract 391). Here we report the exploratory analysis for aggressive B cell lymphomas…

… positron emission tomography combined with computed tomography (FDG PET/CT) is the …
The first investigated whether FDG PET/CT can guide therapy in patients with aggressive NHL…

… PETAL trial is open for patients with newly diagnosed aggressive B cell or T cell non-Hodgkin's
lymphomas … PET scan before starting any lymphoma-directed therapy. Interim-PET is …

… Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) …
lesion is used to assess treatment failure and guide subsequent therapies. A single lesion, …

… 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive …
In conclusion, iPET predicted long-term outcome of aggressive non-Hodgkin lymphoma, but …

… lymphomas [18,19]. This was confirmed in the multicenter positron-emission tomography-guided
therapy of aggressive non-Hodgkin lymphomas (PETAL) trial, which also showed that …